<?xml version="1.0" encoding="UTF-8"?>
<p>This was an unblinded randomized controlled trial. The protocol was approved by the ethics committee of the Affiliated Hospital of Qingdao University, and its ethical approval number is QYFYKYLL201812. It was carried out at the Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, between May 1, 2019 and October 31, 2019. A total of 96 patients were recruited. Eighty-two patients who were eligible for inclusion criteria were randomly assigned into TEAS group (TG) receiving 3-consecutive-day TEAS and control group (CG) at a 1:1 ratio. During the perioperative period, the same ERAS protocol (See 
 <underline>
  <ext-link ext-link-type="uri" xlink:href="http://www.dovepress.com/get_supplementary_file.php?f=292325.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">Appendix 2</ext-link>
 </underline> for detail) was performed on both groups of patients who underwent standard laparoscopic/robot radical gastrectomy. We collected clinical data and blood samples for analysis. This trial has been registered and reviewed at the Chinese Clinical Trial Registry with registration number ChiCTR1900022692. The date of trial registration was April 22, 2019. This study was conducted in accordance with the Declaration of Helsinki.
</p>
